

Re: TREATMENT AND PROPHYLAXIS WITH 4-1BB-BINDING AGENTS

Applicant: Lieping Chen et al.  
Application No.: 12/269,462  
Filing Date: November 12, 2008  
Country: United States  
Your Ref.: 2002-128  
Our Ref.: 07039-0427002

DEAR BARBARA:IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	: Michele Orlando et al.	Art Unit	: 1623
Serial No.	: 10/506,366	Examiner	: Everett White
Filed	: February 2, 2005	Conf. No.	: 1083
Title	: COUPLING LOW-MOLECULAR SUBSTANCES TO A MODIFIED POLYSACCHARIDE		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER UNDER 37 C.F.R. §§ 3.73(b) AND 1.321(C)**

Pursuant to 37 C.F.R. § 3.73(b), FRESENIUS KABI DEUTSCHLAND GMBH, a corporation, certifies that it is the assignee of the entire right, title, and interest in the present application by virtue of a chain of title from the inventors of the present patent application to the current assignee as shown below:

1. From inventors Michele Orlando and Jurgen Hemberger to Biotechnologie Gesellschaft Mittelhessen mbH. The document was recorded in the Patent and Trademark Office at Reel 15820, Frame 0763 on March 2, 2005.
2. From Biotechnologie Gesellschaft Mittelhessen mbH to Fresenius Kabi Deutschland GmbH. The document was recorded in the Patent and Trademark Office at Reel 016023, Frame 0172 on April 6, 2005.
3. From inventors Klaus Sommermeyer, Wolfram Eichner, Sven Frie, Katharina Lutterbeck, Cornelius Jungheinrich, and Roland Scharpf to Fresenius Kabi Deutschland GmbH. The document was recorded in the Patent and Trademark Office at Reel 021090, Frame 0604 on December 15, 2008.

To the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned is empowered to act on behalf of the assignee.

Pursuant to 37 C.F.R. § 1.321(c), the assignee identified above hereby waives and disclaims the terminal portion of the term of the entire patent to be granted upon the present application subsequent to the expiration date of U.S. Patent No. 7,541,328, provided that any patent granted on the present application shall be enforceable only for and during such period that it is commonly owned with U.S. Patent No. 7,541,328.

The assignee identified above does not disclaim any terminal part of any patent granted on the present application prior to the expiration date of the full statutory term of U.S. Patent No. 7,541,328 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term. The full statutory term of any patent includes any term adjustment under 35 U.S.C. § 154 or § 173. Assignee herein does not disclaim or otherwise affect any part of U.S. Patent No. 7,541,328.

This disclaimer runs with any patent granted on the present application and is binding upon the grantee, its successors or assigns.

Please charge \$140 for the required fee pursuant to 37 C.F.R. § 1.20(d), and apply any other charges or credits, to Deposit Account No. 06-1050.

Respectfully submitted,

Date: November 15, 2010

/Elizabeth N. Kaytor/  
Elizabeth N. Kaytor, Ph.D.  
Reg. No. 53,103

Customer Number 26191  
Fish & Richardson P.C.  
Telephone: (612) 335-5070  
Facsimile: (877) 769-7945

Applicant : Michele Orlando et al.  
Serial No. : 10/506,366  
Filed : February 2, 2005  
Page : 3 of 3

Attorney's Docket No.: 14503-0010US1